Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-2570 in Active Psoriatic Arthritis
NCT07315061Phase 2Recruiting
- Sponsor
- InventisBio
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of D-2570 in psoriatic arthritis (PsA) (3 arms), sponsored by InventisBio. Primary endpoint: American College of Rheumatology 20% improvement criteria at 12 weeks. Started Jan 2026; status: recruiting.
02
Drugs
D-2570
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07315061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315061.